Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- Noninvasive ATTR-CM confirmation is powerful, but when guideline-recommended diagnostic criteria are met.
- Monoclonal exclusion remains the essential prerequisite before assigning a nonbiopsy diagnosis.
- A nonbiopsy diagnosis rests on a compatible phenotype, negative monoclonal screen, and concordant bone-avid uptake interpreted together.
- Guidance increasingly links diagnosis with long-term management rather than treating them separately.
What Makes Noninvasive ATTR-CM Confirmation Trustworthy
Noninvasive confirmation is trustworthy when its parts are interpreted together rather than read in isolation. A compatible cardiac phenotype, a negative monoclonal screen, and concordant grade 2 to 3 bone-avid cardiac uptake have to point the same way within the overall diagnostic evaluation before a nonbiopsy diagnosis is justified. The key principle is the integrated interpretation, not just procedural: it's the insistence that imaging, laboratory exclusion, and phenotype agree, which is consistent with current ATTR-CM guidelines and regulation.
Why Monoclonal Exclusion Is the Core Safeguard
Monoclonal exclusion is the core safeguard because it determines whether bone scintigraphy findings can be interpreted as evidence of ATTR-CM. Bone-avid tracer imaging supports ATTR-CM only when a competing light-chain process has been excluded using serum free light chains and serum and urine immunofixation. If the monoclonal screen is abnormal or equivocal, a nonbiopsy diagnosis cannot be established and tissue biopsy with amyloid typing should be considered—the decision point detailed in technetium-99m pyrophosphate (99mTc-PYP) scintigraphy.
Why Guidance Links Confirmation to Longitudinal Management
Current guidance recognizes that establishing an accurate diagnosis is closely linked to subsequent patient management. Following a nonbiopsy diagnosis, appropriate treatment initiation, longitudinal follow-up, and regular clinical assessment are essential components of care. Early identification and accurate diagnosis enable timely therapeutic decisions and support effective long-term disease management.
Practical Checklist
Before accepting a noninvasive (nonbiopsy) ATTR-CM diagnosis, confirm:
- Is the cardiac phenotype consistent with infiltrative cardiomyopathy rather than simply demonstrating wall thickening?
- Have serum free light chains and serum and urine immunofixation excluded a monoclonal process?
- Is bone-avid cardiac uptake graded and concordant, with single-photon emission computerized tomography (SPECT) confirming myocardial rather than blood-pool signal?
- Are phenotype, laboratory exclusion, and imaging findings concordant?
Clinical Decision Point
A noninvasive ATTR-CM diagnosis is justified when a compatible phenotype, a negative monoclonal screen, and concordant graded bone-avid uptake all agree. When the monoclonal screen is abnormal, the scan is equivocal, or the findings conflict, the appropriate next step is toward tissue biopsy with amyloid typing or referral rather than accepting an imaging-only diagnosis.
Frequently Asked Questions
What makes a noninvasive ATTR-CM diagnosis trustworthy?
A trustworthy diagnosis comes from concordance among the clinical, laboratory, and imaging findings: a compatible phenotype, a negative monoclonal screen, and concordant graded bone-avid cardiac uptake interpreted together rather than as separate positive tests.
Why is monoclonal exclusion so important?
Monoclonal exclusion determines what a positive bone-avid scan means. Without excluding a light-chain process, the scan can't be read as confirmation of ATTR-CM, and amyloid light chain (AL) amyloidosis must stay in active consideration.
When should the pathway move to biopsy?
When monoclonal studies are abnormal or equivocal, imaging findings are inconclusive, or clinical findings are discordant. In those cases tissue biopsy with amyloid typing is more reliable than an imaging-only diagnosis.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
- Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance: Journal of the American College of Cardiology
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. Journal of Managed Care & Specialty Pharmacy
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.